IONS Filings — Ionis Pharmaceuticals, Inc. - FilingSpy
IONS
Ionis Pharmaceuticals, Inc.
A biotech pioneer that designs medicines that target RNA—the body's genetic messengers—to treat diseases that were long considered "undruggable." Its medicines include SPINRAZA for spinal muscular atrophy and newer launches like WAINUA, TRYNGOLZA, and DAWNZERA, used mainly by patients with rare, neurological, and cardiometabolic conditions. Founded in 1989, it was originally named Isis Pharmaceuticals after the Egyptian goddess of healing, but renamed itself Ionis in 2015 to shake an unfortunate association with the militant group of the same name.
Ionis's Q2 revenue fell 41% to $268M as a prior-year $280M upfront payment dropped off, while commercial product sales grew 15% to $119M.
The CARDIO-TTRansform trial for eplontersen missed its primary endpoint, removing a major pipeline catalyst. fell 41% to $268 million and the net loss was $115 million, as the absence of a $280 million upfront payment from Ono in the prior year outweighed $100 million in new partner milestones and a 15% increase in commercial product sales. Ionis is now a commercial-stage company with two launched drugs, but its largest late-stage opportunity has failed and operating expenses continue to rise.
Key takeaways
The Phase 3 CARDIO-TTRansform trial for eplontersen in ATTR cardiomyopathy missed its primary endpoint, a clinical setback that removes what had been the largest potential indication in Ionis's pipeline.
fell 41% to $267.9 million, driven almost entirely by the absence of a $280 million upfront payment from Ono for sapablursen that was recognized in Q2 2025.
Commercial rose 15% to $119 million, with DAWNZERA generating $27 million in U.S. net product sales following its August 2025 launch, while TRYNGOLZA sales fell to $5 million after a pre-launch wholesale price reduction.
Section summaries
Management's Discussion and Analysis
Ionis Q2 2026 revenue fell 41% YoY to $268M on lower R&D revenue, while operating expenses rose 19% driven by commercial launches.
⌄
Total decreased to $268M from $452M, primarily due to the absence of a $280M upfront payment from Ono in Q2 2025, partially offset by $100M in new license fees and milestones from Biogen, Recordati, and others.
SG&A expenses rose 66% to $150 million as the company invested in the commercial infrastructure for TRYNGOLZA and DAWNZERA and prepared for a potential zilganersen launch.
The company repaid the remaining $432.5 million principal on its 0% convertible notes due 2026 after the quarter ended, and cash and short-term investments stood at $2.1 billion at quarter-end.
SPINRAZA royalties fell to $42.0 million from $48.0 million a year ago, continuing a decline that had been interrupted by a one-time shipment-timing rebound in Q1 2025.
What changed
The CARDIO-TTRansform trial failure was not flagged in prior filings as a near-term risk; it represents a new and material setback for the eplontersen program, which had been a cornerstone of the partnered pipeline.
TRYNGOLZA sales fell to $5 million from $27.1 million in Q1 2026, a decline management attributed to a pre-launch wholesale price reduction rather than a demand issue, but the sharp drop raises questions about the product's trajectory.
DAWNZERA sales reached $27 million in Q2 2026, up from $15.9 million in Q1 2026, showing sequential growth in its second full quarter on the market.
SG&A expenses rose to $150 million from $150.4 million in Q1 2026, suggesting the near-doubling seen in Q1 2026 may represent a new run-rate rather than a one-time spike.
The $432.5 million convertible note maturity flagged in every prior filing was resolved after the quarter ended, removing a near-term liquidity overhang.
What to watch
FDA decision on olezarsen for severe hypertriglyceridemia, with a of June 30, 2026, which would add a third independent commercial product.
TRYNGOLZA sales trajectory in Q3 2026, to see whether the Q2 decline to $5 million was a one-time pricing adjustment or signals a durable step down in .
DAWNZERA quarterly sales in Q3 2026, to confirm whether the sequential growth from $15.9 million to $27 million continues and at what pace.
SG&A expense level in Q3 2026, to determine whether the $150 million quarterly run-rate holds or rises further as the company prepares for a potential zilganersen launch.
Commercial grew 15% to $119M, driven by $27M in DAWNZERA product sales following its August 2025 launch, while TRYNGOLZA sales fell to $5M after a pre-launch wholesale price reduction.
Operating expenses increased to $370M from $312M, with SG&A up 66% to $150M due to investments in commercializing TRYNGOLZA and DAWNZERA and preparing for a potential zilganersen launch.
R&D expenses were flat at $217M as lower late-stage development costs for eplontersen and olezarsen were offset by higher medical affairs and R&D support costs.
The company repaid its $433M 0% convertible notes due 2026 at maturity, contributing to a net loss of $115M and a decrease in cash and short-term investments to $2.1B.
Key pipeline events included Biogen advancing salanersen into Phase 3, Ono initiating a pivotal trial for sapablursen, and the CARDIO-TTRansform trial for eplontersen missing its primary endpoint.
Quantitative and Qualitative Disclosures About Market Risk
We are exposed to changes in interest rates primarily from our investments in certain short-term investments. We primarily invest our excess cash in highly liquid short-term investments of the U.S. Treasury and reputable financial institutions, corporations, and U.S. government…
⌄
We are exposed to changes in interest rates primarily from our investments in certain short-term investments. We primarily invest our excess cash in highly liquid short-term investments of the U.S. Treasury and reputable financial institutions, corporations, and U.S. government agencies with strong credit ratings. We typically hold our investments for the duration of the term of the respective instrument. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions to manage exposure to interest rate changes. Accordingly, we believe that, while the securities we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments.
We are also exposed to changes in foreign currency exchange rates as we have foreign subsidiaries with functional currencies other than the U.S. dollar. We translate our subsidiaries’ functional currencies into our reporting currency, the U.S. dollar. As a result, our financial position, results of operations and cash flows can be affected by market fluctuations in the foreign currencies to U.S. dollar exchange rate, which are difficult to predict. A hypothetical 10 percent change in foreign exchange rates during any of the periods presented would not have had a material impact on our condensed consolidated financial statements.
Ionis faces material risks from drug commercialization, pricing pressures, clinical setbacks, and intellectual property challenges.
⌄
The failure of the CARDIO-TTRansform Phase 3 trial for eplontersen in ATTR-CM is a newly emphasized clinical risk that could depress the stock price.
New U.S. tariffs of up to 100% on imported patented pharmaceuticals and active ingredients may increase manufacturing costs, though Ionis believes impacts will be limited.
A patent infringement lawsuit filed against Somerset Therapeutics over a generic SPINRAZA ANDA could materially reduce SPINRAZA revenues if successful.
Ionis's independent launches of TRYNGOLZA and DAWNZERA face significant execution risk due to the company's limited commercialization experience and the proximity of planned launches.
Government price negotiation under the Inflation Reduction Act and proposed most favored nation payment models threaten to significantly reduce U.S. drug prices and reimbursement.
Ionis depends on partners like Biogen, AstraZeneca, and Novartis for development and funding, and any termination or deprioritization of these collaborations could halt key programs.